Struthers RS

No ORCID on file · 4 papers in corpus · active 2007-2022

Study types

  • other 2
  • article 1

Condition tags

  • endometriosis 3
2022
Pituitary ·doi:10.1007/s11102-021-01201-z

PurposeEvaluate the pharmacodynamics, pharmacokinetics, and safety of paltusotine, an orally bioavailable, nonpeptide, somatostatin receptor subtype 2 (SST2) agonist being developed for the treatment of acromegaly and neuroendocrine tumors.…

other 2008
Journal of medicinal chemistry ·doi:10.1021/jm8006454

The discovery of novel uracil phenylethylamines bearing a butyric acid as potent human gonadotropin-releasing hormone receptor (hGnRH-R) antagonists is described. A major focus of this optimization was to improve the CYP3A4 inhibition liabi…

article 2008
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jc.2008-1695

CONTEXT: Parenteral administration of peptide GnRH analogs is widely employed for treatment of endometriosis and fibroids and in assisted-reproductive therapy protocols. Elagolix is a novel, orally available nonpeptide GnRH antagonist. OBJE…

other 2007
Endocrinology ·doi:10.1210/en.2006-1213

Suppression of the hypothalamic-pituitary-gonadal axis by peptides that act at the GnRH receptor has found widespread use in clinical practice for the management of sex-steroid-dependent diseases (such as prostate cancer and endometriosis) …